A detailed history of E Fund Management Co., Ltd. transactions in Alkermes Plc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 16,413 shares of ALKS stock, worth $451,029. This represents 0.02% of its overall portfolio holdings.

Number of Shares
16,413
Previous 17,520 6.32%
Holding current value
$451,029
Previous $422,000 8.77%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$23.01 - $28.55 $25,472 - $31,604
-1,107 Reduced 6.32%
16,413 $459,000
Q2 2024

Aug 12, 2024

BUY
$23.21 - $27.24 $62,759 - $73,656
2,704 Added 18.25%
17,520 $422,000
Q1 2024

May 13, 2024

SELL
$26.4 - $32.56 $99,184 - $122,327
-3,757 Reduced 20.23%
14,816 $401,000
Q4 2023

Feb 06, 2024

BUY
$23.37 - $28.68 $63,636 - $78,095
2,723 Added 17.18%
18,573 $515,000
Q3 2023

Nov 13, 2023

BUY
$27.17 - $31.97 $40,809 - $48,018
1,502 Added 10.47%
15,850 $444,000
Q2 2023

Aug 11, 2023

SELL
$28.34 - $33.63 $4,676 - $5,548
-165 Reduced 1.14%
14,348 $449,000
Q1 2023

May 11, 2023

SELL
$25.31 - $29.02 $65,881 - $75,539
-2,603 Reduced 15.21%
14,513 $409,000
Q4 2022

Feb 14, 2023

SELL
$21.94 - $26.24 $59,742 - $71,451
-2,723 Reduced 13.73%
17,116 $447,000
Q3 2022

Nov 14, 2022

BUY
$22.0 - $31.87 $85,646 - $124,069
3,893 Added 24.41%
19,839 $443,000
Q2 2022

Aug 15, 2022

BUY
$26.4 - $30.54 $130,495 - $150,959
4,943 Added 44.92%
15,946 $475,000
Q1 2022

May 12, 2022

BUY
$23.07 - $27.99 $89,119 - $108,125
3,863 Added 54.1%
11,003 $289,000
Q1 2021

May 12, 2021

BUY
$18.21 - $23.2 $130,019 - $165,648
7,140 New
7,140 $133,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.51B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.